CHUGAI PHARMACEUTICAL CO., LTD.

Japan's biopharma industry, once a global leader, declined significantly post-1990s due to economic stagnation, reduced R&D investment, and regulatory hurdles. Recent government initiatives aim to revitalize the sector, including easing drug approval processes and supporting startups, signaling potential for an upswing.

Roche launches cobas® Mass Spec solution, bringing automated, integrated clinical mass spectrometry to routine labs. The solution offers high sensitivity, specificity, and accuracy, with IVDR-compliant assays, aiming to improve patient care, e.g., in hormone therapy monitoring.

The 'Myositis - Pipeline Insight, 2024' report by ResearchAndMarkets.com offers insights into 18+ companies and 20+ pipeline drugs for Myositis, covering drug profiles, therapeutic assessments, and pipeline development activities.

FDA approves Galderma's Nemluvio for moderate-to-severe atopic dermatitis in individuals aged 12 and over, used with topical corticosteroids/calcineurin inhibitors. Supported by Phase III ARCADIA trial results, it marks Galderma's milestone in dermatology innovation. EMA's CHMP also recommends approval for atopic dermatitis and prurigo nodularis.

Chugai Pharmaceutical Co., Ltd. launched a new TV commercial featuring Tori Matsuzaka titled 'Innovation Lab /Cancer Genomic Medicine.' The ad, third in a series, highlights Chugai's commitment to innovative medicines and services through unique technology and science, focusing on cancer genomic medicine. It depicts the progression of cancer treatment from organ-specific to personalized, aiming to provide optimal treatment by analyzing individual cancer genetic mutations. Filmed at Chugai Life Science Park Yokohama, the commercial emphasizes Chugai's goal of personalized cancer treatment.

The FDA approved Nemluvio® (nemolizumab) for treating moderate-to-severe atopic dermatitis in patients 12+ years old, in combination with topical corticosteroids and/or calcineurin inhibitors. Nemluvio, targeting IL-31 receptor alpha, is the first monoclonal antibody to inhibit IL-31 signaling, addressing itch and inflammation. This approval follows its earlier approval for prurigo nodularis in August 2024.

Chugai Pharmaceutical announced Galderma's press release on FDA approval of NEMLUVIO® (nemolizumab) for moderate to severe atopic dermatitis. NEMLUVIO was created by Chugai, with clinical development outside Japan by Galderma.

Galderma's Nemluvio (nemolizumab) receives FDA approval for moderate-to-severe atopic dermatitis in patients 12+ years, in combination with topical corticosteroids and/or calcineurin inhibitors. Nemluvio targets IL-31 receptor alpha, reducing itch and inflammation. Positive phase III ARCADIA trial results showed significant skin clearance and itch relief, with a well-tolerated safety profile.